XML 40 R29.htm IDEA: XBRL DOCUMENT v3.24.3
STOCKHOLDERS' EQUITY (Tables)
 9 Months Ended
Sep. 30, 2024
STOCKHOLDERS' EQUITY [Abstract]  
Warrants Outstanding The following table summarizes the changes in warrants outstanding for the nine months ended September 30, 2024:


   
Shares
    
Weighted
Average
Exercise Price
  
Warrants outstanding at December 31, 2023
    
12,502,906
 
$
2.32
  
Expired
    
(34,800
)
  
$
7.50
  
Granted
    
-
 
$
-
  
Exercised
    
(11,308,702
)
  
$
2.31
  
Warrants outstanding at September 30, 2024
    
1,159,404
 
$
2.26
  
Schedule of Assumptions The following assumptions were used to determine the fair value of options granted during the nine months ended September 30, 2024 and 2023:

   
Nine Months Ended September 30,
  
   
2024
    
2023
  
Expected term
  
5.5 - 6.3 years
    
5.5 - 6.3 years
  
Volatility
  
66%
 
68%

Dividend yield
  
0.0
    
0.0
  
Risk-free interest rate
  
4.16-4.34%

 
4.20-4.24%

Schedule of Option Activity

A summary of the Company’s option activity under the Company’s equity incentive plans and related information is as follows:
   
Shares
    
Weighted
Average
Exercise Price
  
Options outstanding, vested and expected to vest at December 31, 2023
    
5,906,184
    
$
3.38
  
Forfeited
    
(15,723
)
  
$
1.94
  
Expired
    
(221,067
)
  
$
7.34
  
Granted
    
1,511,624
    
$
6.25
  
Exercised     (1,925,498 )   $ 3.85  
Options outstanding, vested and expected to vest at September 30, 2024
    
5,255,520
    
$
3.87
  
                 
Options exercisable
    
2,509,884
    
$
3.10
  
Schedule of Unvested RSU Activity A summary of the Company’s unvested RSU activity and related information is as follows:

   
Shares
    
Weighted
Average Grant
Date Fair Value
  
Balance at December 31, 2023
    
4,657,297
    
$
2.81
  
Granted
    
3,227,188
    
$
7.25
  
Vested
    
(1,701,229
)
  
$
2.59
  
Forfeited
    
(211,688
)
  
$
3.57
  
Balance at September 30, 2024
    
5,971,568
    
$
5.25
  
Schedule of Stock-Based Compensation Expense

Total stock-based compensation expense for all awards granted under the Company’s equity incentive plans for the three and nine months ended September 30, 2024 and 2023 is as follows:
   
Three Months Ended September 30,
    
Nine Months Ended September 30,
  
(in thousands)  
2024
    
2023
    
2024
    
2023
  
Research and development
  
$
24
    
$
12
    
$
65
    
$
27
  
Plasma center operating expenses
    
44
      
41
      
131
      
104
  
Selling, general and administrative
    
2,714
      
1,451
      
6,960
      
3,839
  
Cost of product revenue
    
397
      
191
      
1,027
      
472
  
Total stock-based compensation expense
  
$
3,179
    
$
1,695
    
$
8,183
    
$
4,442